SILVER SPRING, Md. — Pfizer’s Lyrica has an approved new formulation. The Food and Drug Administration on Thursday approved Lyrica CR (pregabalin) controlled-release tablets.
The tablets are indicated as a once-daily treatment for neuropathic pain associated with diabetic peripheral neuropathy and to manage postherpetic neuralgia. It was not approved for fibromyalgia management.
“Lyrica CR was developed to offer patients an effective treatment option with the convenience of once-daily dosing,” Pfizer Global Product Development chief development officer for internal medicine Dr. James Rusnak said. “It provides an important option for patients and health care providers managing these often debilitating pain conditions.”